Millian Craig Stuart
Known title: Chief Operating OfficerCIK: 0001769163
Millian Craig Stuart's purchase track record
Millian Craig Stuart has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/10/2022 | CRBP | $1K | -51.0% | -32.6% | -2.2% |
| 3/10/2022 | CRBP | $4K | -21.6% | -47.6% | -5.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRBP | ▲ Buy | Open Market | 5,000 | $1K | 8/10/2022 | View on chart |
| CRBP | ▲ Buy | Open Market | 10,000 | $4K | 3/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study
Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.